Dow Jones futures rebound as OpenAI sales outlook calms tech selloff
Dow Jones futures inch higher by 0.05% to trade near 51,520 during European hours on Friday. S&P 500 futures gain 0.33% to around 7,840, while Nasdaq 100 futures rise 0.82% to near 31,220.
US futures indices experienced a rebound as market sentiment recovered, driven by reports that OpenAI expects its annualized revenue to reach or exceed $70 billion by year-end. The upbeat projection helped ease investor concerns triggered by earlier reports indicating that the company's revenue had fallen $20 billion short of previously signaled levels.
The early optimism followed a mixed regular trading session on Wall Street on Thursday, where an initial, underwhelming revenue report from OpenAI led to a late-day selloff in technology and semiconductor stocks. Reports had suggested that OpenAI’s annualized revenue stood at $50 billion at the end of September, substantially below the widely circulated $68 billion figure reported the prior month. Consequently, the S&P 500 dropped 0.47%, and the Nasdaq Composite fell 1.25%, while the Dow Jones Industrial Average managed a modest 0.1% gain.
Adding to the dynamic backdrop, crude oil prices pulled back after US President Donald Trump stated that the US would refrain from military action against Iran ahead of the November midterm elections. Although lower energy costs helped alleviate immediate inflation anxieties, persistently high US Treasury yields continued to cast a shadow over the broader market outlook.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Reports of iPhone production cuts send Apple shares lower
October 9 – According to Nikkei Asia (link), Apple has asked its suppliers to cut production of the new iPhone 18 Pro model due to weak demand, resulting in Apple (AAPL.O) shares falling 1.8% in premarket trading to $334.21. The report states that, against the backdrop of soaring memory chip costs and rising prices, the component orders for October have been reduced by at least 15% compared to initial requirements. Apple has not yet responded to a Reuters request for comment. The current stock price is about 1% lower than the all-time intraday high of $345.34 reached on September 22. According to data compiled by the London Stock Exchange Group (LSEG), the average rating from 43 analysts covering the stock is "Buy," with a median target price of $330. (For the convenience of non-English speakers, Reuters provides automated translations of its report into several other languages. As automated translations may contain errors or lack the required context, Reuters does not guarantee the accuracy of the automated translation and provides it solely for reader convenience. Reuters accepts no liability for any damage or loss resulting from use of the automated translation function.)
Citi maintains a “Neutral” rating on DocuSign (DOCU.O): IAM platform migration shows initial effectiveness, double-digit growth still needs "validation"
Citi published a research report maintaining a "Neutral" rating on the e-signature and agreement cloud platform DocuSign, with a target price of $72.
Market Chatter: Mastercard CEO Says Cross-Border Payments Is Currently Stablecoin's Best Use Case
07:14 AM EDT, 10/09/2026 (MT Newswires) -- Mastercard (MA) Chief Executive Officer Michael Miebach said that cross-border payments currently present the best use case for stablecoins, Bloomberg reported Friday, citing an interview. Mastercard is interested in stablecoins for moving money rather than as an investment, Miebach said, according to the report. The company is an investor in a new firm called Open Standard, which recently issued a US dollar-pegged stablecoin, the report added. (Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Humana shares soar as it becomes the biggest beneficiary of the 2027 Medicare star ratings.
Reuters, October 9 – In pre-market trading on Friday, shares of Humana (stock code: HUM.N) rose by 15%. Analysts said the health insurer is set to be the biggest beneficiary of the new 2027 Medicare Advantage star ratings. Humana stated that, with improvements in healthcare quality and member experience indicators, 95% of its Medicare Advantage members will be enrolled in plans rated four stars or higher by 2027, a substantial jump from 20% in 2026 (link). JPMorgan analysts noted that they had previously projected this ratio to be between 60% and 70%. The U.S. Department of Health and Human Services uses a one- to five-star scale to rate Medicare Advantage and prescription drug plans. Higher ratings lead to government bonuses worth billions of dollars and can help attract more members. Analysts noted that Humana’s ratings performance outpaced its larger competitors: JPMorgan expects the proportion of UnitedHealth Group’s (UNH.N) plans rated four stars or higher to decrease from 81% to about 67%, while CVS Health’s (CVS.N) ratio will fall from 84% to about 70%. The U.S. Department of Health and Human Services said Thursday night that, overall, about 71% (link) of Medicare Advantage prescription drug plan enrollees will be in contracts rated four stars or higher in 2027. Evercore ISI analyst Elizabeth Anderson said that Humana had improved in prescription drug plan quality, health plan quality, and readmission rates. She added, “This improvement reflects management’s increased focus on these metrics over the past year.” Health insurers provide Medicare Advantage plans for the government to adults aged 65 and older and people with disabilities.
